Allschwil, Switzerland – June 20, 2018  Idorsia Ltd (SIX: IDIA) today announced that the first patient has been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults. Hypertension, […]